share_log

Avalo Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Great Point Partners, LLC(0.26%),Dr. Jeffrey R. Jay, M.D.(0.26%), etc.

SEC announcement ·  Feb 15 06:35
Summary by Futu AI
Avalo Therapeutics, Inc. has been the subject of a Schedule 13G/A amendment filing with the United States Securities and Exchange Commission (SEC) on December 31, 2023. The filing indicates that Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Mr. Ortav Yehudai, have reported shared voting and dispositive power over 2,085 shares of Avalo Therapeutics' common stock, which represents 0.26% of the company's class of securities. The shares in question are associated with warrants that are subject to a Beneficial Ownership Cap, preventing the exercise of the warrants if it would result in ownership exceeding 9.99% of the outstanding common stock. The filing, dated February 14, 2024, also includes a joint filing agreement between the reporting persons, indicating their intention to file this statement jointly in accordance with SEC regulations. The reporting persons have disclaimed beneficial ownership of the shares except to the extent of their pecuniary interest, and the filing certifies that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
Avalo Therapeutics, Inc. has been the subject of a Schedule 13G/A amendment filing with the United States Securities and Exchange Commission (SEC) on December 31, 2023. The filing indicates that Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Mr. Ortav Yehudai, have reported shared voting and dispositive power over 2,085 shares of Avalo Therapeutics' common stock, which represents 0.26% of the company's class of securities. The shares in question are associated with warrants that are subject to a Beneficial Ownership Cap, preventing the exercise of the warrants if it would result in ownership exceeding 9.99% of the outstanding common stock. The filing, dated February 14, 2024, also includes a joint filing agreement between the reporting persons, indicating their intention to file this statement jointly in accordance with SEC regulations. The reporting persons have disclaimed beneficial ownership of the shares except to the extent of their pecuniary interest, and the filing certifies that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.